Publications by authors named "V G Gonzalez Nicolini"
Background: Multiple Myeloma (MM) is the second most common hematological malignancy, characterized by the accumulation of monoclonal plasmocytes in the bone marrow. Despite advancements with proteasome inhibitors, immunomodulatory agents, and CD38-targeting antibodies, MM remains largely incurable due to resistant clones and frequent relapses. The success of the proteasome inhibitor bortezomib (BTZ) in MM treatment highlights the critical role of the ubiquitin-proteasome system (UPS) in this disease.
View Article and Find Full Text PDFArticle Synopsis
- T-cell responses require two signals for effective activation: engagement of T-cell receptors (signal 1) and additional costimulatory signals (signal 2), which T-cell bispecific antibodies (TCBs) can provide by targeting specific antigens and CD3ε.
- The study introduces CD19-CD28, a bispecific CD19-targeted CD28 agonist, designed to enhance the effectiveness of glofitamab, a TCB targeting malignant B cells, by delivering the crucial costimulatory signal 2 needed for stronger T-cell responses.
- Initial results show that combining glofitamab with CD19-CD28 and the 4-1BB agonist significantly improves long
Article Synopsis
- The study investigates the immunocytokine cergutuzumab amunaleukin (CEA-IL2v) and its effects on patients with advanced carcinoembryonic antigen-positive tumors, focusing on its safety, pharmacodynamics, and the issue of anti-drug antibodies (ADA).
- Researchers explored using obinutuzumab, a treatment that depletes B-cells, as a strategy to reduce ADA development while analyzing its effects in clinical trials.
- Results indicated that patients pretreated with obinutuzumab showed a significantly lower incidence of ADAs, suggesting it could be a viable approach to enhance the safety and efficacy of CEA-IL2v therapy, although some increased liver toxicity was noted in combination treatments
Purpose: Combination of chemotherapy with programmed cell death 1 (PD-1) blockade is a front-line treatment for lung cancer. However, it remains unknown whether and how chemotherapy affects the response of exhausted CD8 T cells to PD-1 blockade.
Experimental Design: We used the well-established mouse model of T-cell exhaustion with chronic lymphocytic choriomeningitis virus (LCMV) infection to assess the effect of chemotherapy (cisplatin+pemetrexed) on T-cell response to PD-1 blockade, in the absence of the impact of chemotherapy on antigen release and presentation observed in tumor models.
Overactivation of the mitogen-activated protein kinase (MAPK) pathway is a critical driver of many human cancers. However, therapies directly targeting this pathway lead to cancer drug resistance. Resistance has been linked to compensatory RAS overexpression, but the mechanisms underlying this response remain unclear.
View Article and Find Full Text PDF